1-20 of 39
Jan H.M. Schellens
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma

Available to Purchase
Alaa Embaby, Sanne C.F.A. Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J.C. Kluin, Cor Lieftink, Christopher G. Smith, Christian U. Blank, Johannes V. van Thienen, John B.A.G. Haanen, Neeltje Steeghs, Frans L. Opdam, Jos H. Beijnen, Alwin D.R. Huitema, Rene Bernards, Jan H.M. Schellens, Sofie Wilgenhof
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3157–3166.
https://doi.org/10.1158/1078-0432.CCR-23-3171
Published: 01 August 2024
View article titled, A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Open the PDF for A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Available to Purchase
Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen, Heike M.U. Peulen, Erik van Werkhoven, Adrianus J. de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H.M. Schellens, Neeltje Steeghs, Marcel Verheij, Baukelien van Triest
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1256–1266.
https://doi.org/10.1158/1078-0432.CCR-20-2551
Published: 01 March 2021
View article titled, Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
Open the PDF for Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Free
Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O'Dwyer, Filip De Vos, Eric Van Cutsem, John M. Millholland, Jan C. Brase, Fatima Rangwala, Eduard Gasal, Ryan B. Corcoran
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2466–2476.
https://doi.org/10.1158/1078-0432.CCR-19-3579
Published: 01 June 2020
View article titled, BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Open the PDF for BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

Free
Vincent A. de Weger, Frederik E. Stuurman, Stijn L.W. Koolen, Johannes J. Moes, Jeroen J.M.A. Hendrikx, Emilia Sawicki, Bas Thijssen, Marianne Keessen, Hilde Rosing, Marja Mergui-Roelvink, Alwin D.R. Huitema, Bastiaan Nuijen, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5466–5474.
https://doi.org/10.1158/1078-0432.CCR-17-2299
Published: 13 September 2019
View article titled, A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir
Open the PDF for A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir in another window
Journal Articles

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Free
Daniel D. Von Hoff, Drew W. Rasco, Elisabeth I. Heath, Pamela N. Munster, Jan H.M. Schellens, Nicolas Isambert, Christophe Le Tourneau, Bert O'Neil, Ron H.J. Mathijssen, Jose A. Lopez-Martin, W. Jeff Edenfield, Miguel Martin, Patricia M. LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4072–4080.
https://doi.org/10.1158/1078-0432.CCR-17-3716
Published: 04 September 2018
View article titled, Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Open the PDF for Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Free
Udai Banerji, Emma J. Dean, J. Alejandro Pérez-Fidalgo, Gerald Batist, Philippe L. Bedard, Benoit You, Shannon N. Westin, Peter Kabos, Michelle D. Garrett, Mathew Tall, Helen Ambrose, J. Carl Barrett, T. Hedley Carr, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P.O. Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H.M. Schellens
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (9): 2050–2059.
https://doi.org/10.1158/1078-0432.CCR-17-2260
Published: 30 April 2018
View article titled, A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers
Open the PDF for A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Free
Didier Meulendijks, Wolfgang Jacob, Emile E. Voest, Morten Mau-Sorensen, Maria Martinez-Garcia, Alvaro Taus, Tania Fleitas, Andres Cervantes, Martijn P. Lolkema, Marlies H.G. Langenberg, Maja J. De Jonge, Stefan Sleijfer, Ji-Youn Han, Antonio Calles, Enriqueta Felip, Sang-We Kim, Jan H.M. Schellens, Sabine Wilson, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Suzana Vega-Harring, Rajiv Dua, Maitram Nguyen, Lori Steiner, Celine Adessi, Francesca Michielin, Birgit Bossenmaier, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5406–5415.
https://doi.org/10.1158/1078-0432.CCR-17-0812
Published: 14 September 2017
View article titled, Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Open the PDF for Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Free
Jill J.J. Geenen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (16): 4540–4544.
https://doi.org/10.1158/1078-0432.CCR-17-0520
Published: 14 August 2017
View article titled, Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer
Open the PDF for Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer in another window
Journal Articles

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Free
Remy B. Verheijen, Sander Bins, Ron H.J. Mathijssen, Martijn P. Lolkema, Leni van Doorn, Jan H.M. Schellens, Jos H. Beijnen, Marlies H.G. Langenberg, Alwin D.R. Huitema, Neeltje Steeghs
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5738–5746.
https://doi.org/10.1158/1078-0432.CCR-16-1255
Published: 30 November 2016
View article titled, Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
Open the PDF for Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients in another window
Journal Articles

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Free
Pamela Munster, Rahul Aggarwal, David Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer Specht, Petronella O. Witteveen, Theresa L. Werner, E. Claire Dees, Emily Bergsland, Neeraj Agarwal, Joseph F. Kleha, Michael Durante, Laurel Adams, Deborah A. Smith, Thomas A. Lampkin, Shannon R. Morris, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 1932–1939.
https://doi.org/10.1158/1078-0432.CCR-15-1665
Published: 14 April 2016
View article titled, First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Open the PDF for First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies in another window
Includes: Supplementary data
Journal Articles

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

Free
Didier Meulendijks, Ulrik N. Lassen, Lillian L. Siu, Alwin D.R. Huitema, Vaios Karanikas, Morten Mau-Sorensen, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Karen Wang, Mark DeMario, Glenwood D. Goss, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 858–867.
https://doi.org/10.1158/1078-0432.CCR-15-1506
Published: 14 February 2016
View article titled, Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Open the PDF for Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors in another window
Journal Articles

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Free
Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, Alvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas Kanonnikoff, Andres Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau Soerensen, Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Celine Adessi, Francesca Michielin, Keelara Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Martin Weisser, Ulrik N. Lassen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 877–885.
https://doi.org/10.1158/1078-0432.CCR-15-1683
Published: 14 February 2016
View article titled, First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Open the PDF for First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

Free
Ulrik N. Lassen, Didier Meulendijks, Lilian L. Siu, Vaios Karanikas, Morten Mau-Sorensen, Jan H.M. Schellens, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Ka Wang, Mark DeMario, Glenwood D. Goss
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 258–266.
https://doi.org/10.1158/1078-0432.CCR-14-1334
Published: 14 January 2015
View article titled, A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
Open the PDF for A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers in another window
Includes: Supplementary data
Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Free
Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5663–5671.
https://doi.org/10.1158/1078-0432.CCR-14-0719
Published: 13 November 2014
View article titled, Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Open the PDF for Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study in another window
Includes: Supplementary data
Journal Articles

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Free
Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, Veronique Dieras, Jan H.M. Schellens, Jean-Philippe Spano, Mark R. Middleton, Emiliano Calvo, Luiz Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber-Bodéré, Jean J.L. Tessier, Wilfried Ernst Erich Eberhardt, Michel Paques, Ernesto Guarin, Valerie Meresse, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4251–4261.
https://doi.org/10.1158/1078-0432.CCR-14-0341
Published: 13 August 2014
View article titled, Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
Open the PDF for Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations in another window
Includes: Supplementary data
Journal Articles

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

Free
Fan Lin, Serena Marchetti, Dick Pluim, Dilek Iusuf, Roberto Mazzanti, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2084–2095.
https://doi.org/10.1158/1078-0432.CCR-12-3105
Published: 15 April 2013
View article titled, Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues
Open the PDF for Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues in another window
Journal Articles

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Free
Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber-Bodéré, Veronique Dieras, Max E. Scheulen, Avinash Gupta, Vanesa Lopez-Valverde, Zhi-Xin Xu, Ruediger Rueger, Jean J.L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jan H.M. Schellens, Wilfried Ernst Erich Eberhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4794–4805.
https://doi.org/10.1158/1078-0432.CCR-12-0868
Published: 30 August 2012
View article titled, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Free
Maria Nieto, Jeanett Borregaard, Jens Ersbøll, George J.A. ten Bosch, Barbara van Zwieten-Boot, Eric Abadie, Jan H.M. Schellens, Francesco Pignatti
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6608–6614.
https://doi.org/10.1158/1078-0432.CCR-11-1734
Published: 31 October 2011
View article titled, The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Open the PDF for The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use in another window
Journal Articles

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Free
Stijn L.W. Koolen, Petronella O. Witteveen, Robert S. Jansen, Marlies H.G. Langenberg, Roelien H. Kronemeijer, Annemarie Nol, Ignacio Garcia-Ribas, Sophie Callies, Karim A. Benhadji, Christopher A. Slapak, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6071–6082.
https://doi.org/10.1158/1078-0432.CCR-11-0353
Published: 14 September 2011
View article titled, Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors in another window
Journal Articles

SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Response

Free
Maarten J. Deenen, Jan H.M. Schellens, Annemieke Cats
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5835–5836.
https://doi.org/10.1158/1078-0432.CCR-11-1746
Published: 01 September 2011
View article titled, SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Response
Open the PDF for SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Response in another window